{
    "code": "52027025",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027025",
    "time": "2017-09-08 03:33:37",
    "許可證字號": "衛部藥輸字第027025號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "110\/12\/20",
    "發證日期": "105\/12\/20",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202702500",
    "中文品名": "美加柔持續性藥效膜衣錠300毫克",
    "英文品名": "Megazon Prolonged-Release Tablets 300mg",
    "適應症": "治療思覺失調症、雙極性疾患的鬱症發作、躁症發作或混合發作。對於抗鬱劑單一藥物治療效果不佳的重鬱症(MDD)病人，可作為重鬱症發作的附加治療。開始治療之前，臨床醫師應該考慮Quetiapine XR的安全性。",
    "劑型": "164持續性藥效膜衣錠",
    "包裝": "2-1000粒PVC\/PCTFE\/Alu鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "QUETIAPINEFUMARATE"
    ],
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "620110S434  西海生技股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F160044000  PHARMATHEN INTERNATIONAL S.A.",
        "製造廠廠址": "INDUSTRIAL PARK, 5TH BLOCK, 69300, SAPES, RODOPI, GREECE",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200037620",
            "成分名稱": "QUETIAPINE FUMARATE",
            "含量描述": "(equivalent to Quetiapine.....300mg)",
            "含量": "345.3600000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "20170627_50 mg+150 mg+200 mg+300 mg 仿單-106-07-04.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027025&Seq=002&Type=9"
        },
        {
            "title": "020270250003_Megazon PRT 300 mg_outer-106-01-17.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027025&Seq=002&Type=8"
        }
    ]
}